国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (7): 496-500.doi: 10.3760/cma.j.issn.1673-422X.2015.07.005

• 论著 • 上一篇    下一篇

剂量密集顺铂联合氟尿嘧啶治疗远处转移鼻咽癌研究

梁永,冯坚,陈柏裕,梁维朝,陈科权,高伟伟,许耀灿   

  1. 37200 广西壮族自治区桂平市人民医院肿瘤科
  • 出版日期:2015-07-08 发布日期:2015-05-26
  • 通讯作者: 梁永 E-mail:gxgpliangyong@163.com
  • 基金资助:

    贵港市科学研究与技术开发项目（贵科攻0807004）

Clinic study of dosedense cisplatin and 5fluorouracil in patients with distant metastatic nasopharyngeal carcinoma

Liang Yong, Feng Jian, Chen Boyu, Liang Weichao, Chen Kequan, Gao Weiwei, Xu Yaocan   

  1. Department of Oncology, Guiping People′s Hospital of Guangxi Zhuang Autonomous Region, Guiping 537200, China
  • Online:2015-07-08 Published:2015-05-26
  • Contact: Liang Yong E-mail:gxgpliangyong@163.com

PDF

1209

被引次数

1

摘要： 目的探讨剂量密集顺铂联合氟尿嘧啶（PF方案）治疗远处转移鼻咽癌的疗效及安全性。方法2008年4月1日至2014年4月30日共168例患者入组，采用数字随机表法按1∶1将患者随机分到传统组（83例）和剂量密集组（85例）。2组患者均接受PF方案治疗，传统组每28天1次，剂量密集组每14天1次。研究主要终点是PFS，第二终点是OS、不良反应和客观缓解率。结果剂量密集组中位PFS，中位OS，1、2、3年生存率分别为13.3个月、20.2个月、80.2%、36.0%、16.1%，均优于传统组的10.0个月（χ2＝24.47，P=0.000）、16.1个月（χ2＝16.65，P=0.000）、59.6%（χ2＝8.41，P=0.004）、10.1%（χ2＝16.96，P=0.000）、0（χ2＝14.91，P=0.000）。两组完全缓解率和客观缓解率分别为16.5%和3.6%（χ2=7.63，P=0.006）、84.7%和54.2%（χ2=18.47，P=0.000）。剂量密集组3～4级不良发生率高于传统化疗组（38.8%∶6.0%，χ2=25.81，P=0.000），但可耐受。结论剂量密集PF方案治疗远处转移鼻咽癌患者疗效优于传统化疗，且不良反应可耐受，可作为患者治疗新选择。

关键词: 鼻咽肿瘤, 药物疗法, 剂量密集

Abstract: ObjectiveTo investigate the efficacy and tolerability of dosedense chemotherapy with cisplatin plus 5fluorouracil (PF regimen) in distant metastatic nasopharyngeal carcinoma (NPC) patients. MethodsFrom April 1, 2008 to April 30, 2014, 168 patients were assigned to traditional group (n=83) and dosedense group (n=85) using digital random table in 1∶1 ratio. All patients received PF regimen, and once every 28 days in traditional group and once every 14 days in dosedense group. The primary endpoint was progressionfree survival (PFS) and the secondary endpoint was overall survival (OS), toxicity and response rate. ResultsThe median PFS, median OS, 1, 2, 3year survival rate, complete response rate and objective response rate were significantly improved in dosedense group which were 13.3 months, 20.2 months, 80.2%, 36.0%, 16.1%, 16.5%, 84.7%, and those in control group were 10.0 months, 16.1 months, 59.6%, 10.1%, 0, 3.6%, 54.2% respectively (χ2＝24.47, P=0.000; χ2＝16.65, P=0.000; χ2＝8.41, P=0.004; χ2＝16.96, P=0.000; χ2＝14.91, P=0.000; χ2=7.63, P=0.006; χ2=18.47, P=0.000). The rates of grade 34 adverse events in dosedense and traditional group were 38.8% and 6.0% (χ2=25.81, P= 0.000). ConclusionDosedense chemotherapy of PF is more efficient and acceptable toxic than the traditional one. It can be a new treatment option for patients with distant metastases of NPC.

Key words: Nasopharyngeal neoplasms, Drug therapy, Dosedense